Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children
22 janv. 2020 09h00 HE
|
Q2Earth, Inc
Palm Beach, FL, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Q2Earth, Inc. (OTCQB: QPWR) (the “Company” or “Q2”) announced today that it has signed an Exclusive Dealing Option Agreement to provide the Company...
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
04 mai 2018 08h45 HE
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company,...